The brand's ingenious new 'Classics' ad sees the brand highlighting instances of its name appearing in classic books, by ...

Cardinal Health Inc. closed 5.54% short of its 52-week high of $139.50, which the company achieved on April 3rd.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Cardinal Health (CAH – Research Report). The ...

BofA raised the firm’s price target on Cardinal Health (CAH) to $155 from $150 and keeps a Buy rating on the shares. The recent introduction of ...

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

BofA raised the firm’s price target on McKesson (MCK) to $755 from $665 and keeps a Buy rating on the shares. The recent introduction of ...

The stock's rise snapped a four-day losing streak.

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S. commercial ...

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

This was the stock's third consecutive day of losses.